

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Ertugliflozin in triple therapy for treating type 2 diabetes ID1160

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company/sponsor</u></p> <ul style="list-style-type: none"> • Merck Sharp & Dohme (ertugliflozin) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • BEMDA: Black and Ethnic Minority Diabetes Association • Black Health Agency • Diabetes Research and Wellness Foundation • Diabetes UK • Muslim Council of Britain • Network of Sikh Organisations • South Asian Health Foundation • Specialised Healthcare Alliance • Stroke Association <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association for the Study of Obesity • Association of British Clinical Diabetologists • British Atherosclerosis Society • British Geriatrics Society • British Society for Haematology • British Society for Haemostasis and Thrombosis • British Thoracic Society • Clinical Leaders of Thrombosis • Diabetes Specialist Nurses • Primary Care Diabetes Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society for Endocrinology • Society for Vascular Nurses • Society for Vascular Technology 	<p><u>General commentators</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Diabetes UK Cymru • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Comparators</u></p> <ul style="list-style-type: none"> • Accord healthcare (gliclazide, glimepiride, pioglitazone, tolbutamide) • AstraZeneca (exenatide, dapagliflozin, saxagliptin) • Aurobindo Pharma (glibenclamide, gliclazide) • Boehringer Ingelheim (empagliflozin, linagliptin) • Bristol laboratories (gliclazide) • Concordia International Corp (gliclazide) • Consilient Health (gliclazide, pioglitazone) • Eli Lilly UK (dulaglutide) • GlaxoSmithKline (albiglutide) • Kent Pharmaceuticals (tolbutamide) • Eli Lilly UK (dulaglutide, insulin)

<ul style="list-style-type: none"> • TREND UK • UK Clinical Pharmacy Association • UK Health Forum <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England • NHS West Hampshire CCG • NHS West Kent CCG • Welsh Government 	<ul style="list-style-type: none"> • Lupin Healthcare (gliclazide) • Merck Sharp and Dohme (sitagliptin) • Mylan UK (glipizide, pioglitazone) • Napp Pharmaceuticals (canagliflozin) • Novartis Pharmaceuticals (vildagliptin) • Novo Nordisk Limited (insulin, liraglutide) • Pfizer (glipizide) • Sandoz (pioglitazone) • Sanofi (insulin, lixisenatide) • Servier Laboratories (gliclazide) • Sun Pharma (pioglitazone) • Takeda UK (alogliptin, pioglitazone) • Wockhardt UK (glibenclamide, gliclazide, insulin) • Zentiva UK (glimepiride, pioglitazone) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • British Society for Cardiovascular Research • Cardiac and Cardiology Research Dept, Barts • Cochrane Heart Group • Cochrane Hypertension Group • Cochrane Metabolic & Endocrine Disorders Group • Cochrane Stroke Group • European Council for Cardiovascular Research • Heart Research UK • MRC Clinical Trials Unit • National Institute for Health Research • The Society for Research in Rehabilitation • Wellcome Trust <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales
---	--

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that manufactures the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that manufactures the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹Non-company consultees are invited to submit statements relevant to the group they are representing.